JPM26: Integra resets by fixing supply and riding reimbursement tailwinds

Integra LifeSciences used its update at the ongoing 2026 J.P. Morgan Healthcare Conference in San Francisco to frame 2025 and 2026 as a deliberate transition period. The company described a shift from disruption and remediation toward more predictable execution, supported by product relaunches, a more resilient supply chain, and reimbursement changes that could make parts of its wound portfolio more economically attractive in outpatient settings. Integra spent a meaningful portion of the presentation on ...